drugset / Trial / NCT04160026
Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya
Phase 4
Completed
1600 enrolled
Liverpool School of Tropical Medicine
Kamuzu University of Health Sciences · collabKenya Medical Research Institute · collabKilimanjaro Christian Medical Centre, Tanzania · collabLondon School of Hygiene and Tropical Medicine · collabNational Institute for Medical Research, Tanzania · collabUniversity of Bergen · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This multi-centre study will compare the acceptability, feasibility, cost and incremental cost-effectiveness of intermittent preventive treatment (IPTp) with dihydroartemisinin-piperaquine (DP) with or without azithromycin to the current strategy of IPTp with sulphadoxine-pyrimethamine (SP) to prevent malaria, sexually transmitted and reproductive tract infections in HIV-uninfected pregnant women (IMPROVE).
Timeline
- Start
- 2019-11-11
- Primary completion
- 2020-07-31
- Completion
- 2020-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dihydroartemisinin-piperaquine | Unknown | 40 mg | — |
| Subject | Dihydroartemisinin-piperaquine | Unknown | 320 mg | — |
| Comparator | Sulfadoxine-pyrimethamine | Small molecule | 25 mg | — |
| Comparator | Sulfadoxine-pyrimethamine | Small molecule | 500 mg | — |